Abstract
Enasidenib (Idhifa (R)) is an oral isocitrate dehydrogenase-2 (IDH2) inhibitor developed by Celgene Corporation under a global, exclusive license from......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
